Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01728064 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of EPI-743 in Patients With Friedreich's Ataxia
A Phase 2 study, sponsored by PTC Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT01728064: Completed Phase 2 study, sponsored by PTC Therapeutics.
NCT01728064 is a Phase 2 study that has completed, run by PTC Therapeutics. The registered enrollment target is 60 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (55% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01728064, a Phase 2 study, has completed, sponsored by PTC Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
The purpose of this study is to examine the effects of EPI-743 on visual function and neurologic function in patients with Friedreich's ataxia.
Primary Outcome
Low contrast visual acuity
Interventions
- DRUG Placebo
- DRUG EPI-743 400 mg
- DRUG EPI-743 200 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2012-12-31 |
| Est. Completion | 2016-02-29 |
| Phase | Phase 2 |
What the finished NCT01728064 record still lists
NCT01728064 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (55% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01728064 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01728064 about?
NCT01728064 is a clinical study titled "Safety and Efficacy of EPI-743 in Patients With Friedreich's Ataxia". The purpose of this study is to examine the effects of EPI-743 on visual function and neurologic function in patients with Friedreich's ataxia.
What is the current status of trial NCT01728064?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2012-12-31. Estimated completion is 2016-02-29.
What interventions are being tested in trial NCT01728064?
The interventions under investigation include: Placebo (DRUG), EPI-743 400 mg (DRUG), EPI-743 200 mg (DRUG).
Who is sponsoring clinical trial NCT01728064?
This trial is sponsored by PTC Therapeutics, which has 52 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01728064's enrollment target sits among peer trials
60 1027th of 2000 higher than 868 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI